title: Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
abstract: The records of 125 patients with nonmucinous invasive ovarian adenocarcinoma who underwent cytoreductive surgery, cisplatin-based combination chemotherapy, and second-look laparotomy were analyzed to correlate pre-second-look serum CA-125 levels with the size of residual ovarian cancer. The majority of patients with negative second-look laparotomy had normal serum CA-125 levels (46/50 or 92%). Of the 75 patients with positive second-look, 56 (75%) had normal CA-125 levels preoperatively. Twenty-three of twenty-four (96%) patients with residual disease less than or equal to 1 cm had normal CA-125 levels as did 20 of 28 (71%) patients with disease 1.1-2.0 cm. Although elevated serum CA-125 levels were invariably associated with visible/gross disease and increasing size of residual disease tended to be associated with increasing elevations of CA-125, normal CA-125 levels often occurred in the presence of large-volume (greater than 2 cm) disease (13/23, 57% of patients). The considerable overlap of serum CA-125 levels for all sizes of residual disease precluded precise prediction of residual disease size based on serum CA-125 level alone.
authors.affiliation: Division of Gynecologic Oncology, Watson Clinic, Lakeland, Florida 33804-5000.
authors.forename: B
authors.initials: B
authors.lastname: Patsner
authors.forename: J W
authors.initials: JW
authors.lastname: Orr
authors.forename: W J
authors.initials: WJ
authors.lastname: Mann
authors.forename: P T
authors.initials: PT
authors.lastname: Taylor
authors.forename: E
authors.initials: E
authors.lastname: Partridge
authors.forename: T
authors.initials: T
authors.lastname: Allmen
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D007813:Laparotomy; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012086:Reoperation
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor